3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
5
NIH
1
NETWORK
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
3
Sarcoma
2
Lymphoid
2
Gastrointestinal
2
Other hematologic neoplasm
1
Classical hematology
1
Conditions
Anemia, Refractory, with Excess of Blasts
10
Myelodysplastic Syndromes
8
Leukemia
7
Leukemia, Myelomonocytic, Chronic
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Leukemia, Myeloid, Acute
5
Anemia, Refractory
5
Myeloproliferative Disorders
4
Myelodysplastic-Myeloproliferative Diseases
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Anemia
3
Thrombocytopenia
2
Neutropenia
2
Neoplasms
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myelomonocytic, Juvenile
2
Hodgkin Disease
2
Congenital Abnormalities
2
Anemia, Sickle Cell
2
Anemia, Aplastic
2
Wilms Tumor
1
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Tourette Syndrome
1
Testicular Neoplasms
1
Stress Disorders, Post-Traumatic
1
Squamous Cell Carcinoma of Head and Neck
1
Sleep Initiation and Maintenance Disorders
1
Severe Acute Respiratory Syndrome
1
Seizures
1
Interventions
Medical Marijuana
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NETWORK
×
Acquired Immunodeficiency Syndrome
×
Classical hematology
×
Clear all
NCT03944447
2022-06-02
OMNI-Can
OMNI Medical Services, LLC
Phase 2
Unknown
200,000 enrolled